Search

Your search keyword '"Go Yokouchi"' showing total 2 results
Start Over Author "Go Yokouchi" Topic glomerular filtration rate
2 results on '"Go Yokouchi"'

1. Renoprotective effect of chronic treatment with sodium-glucose cotransporter 2 inhibitors and its associated factors in Japanese patients with chronic heart failure and diabetes

Author

Go Yokouchi, Takeshi Horio, Naoki Matsumoto, Kohei Fukuda, Ryutaro Yoshimura, Ryosuke Fujiwara, Yujiro Matsuoka, Yuya Sakamoto, Yoshio Iwashima, Yoshiyuki Oshiro, Kohei Fujimoto, and Noriaki Kasayuki

Subjects
SGLT2 inhibitor, Renal function, Glomerular filtration rate, Venous congestion, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Background: Recent clinical trials have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors have beneficial effects on renal function in heart failure patients. This study confirmed the renoprotective effect of treatment with SGLT2 inhibitors in Japanese patients with chronic heart failure and diabetes and further investigated what cardiac/hemodynamic and noncardiac factors are involved in its effect. Methods: Eligible 50 outpatients with chronic heart failure and type-2 diabetes mellitus chronically taking SGLT2 inhibitors were enrolled. Annual changing rates of estimated glomerular filtration rate (eGFR) were compered before and after treatment with SGLT2 inhibitors and the associations of the change in eGFR slope after SGLT2 inhibitor administration with changes in various clinical and echocardiographic parameters were evaluated. Results: The mean follow-up periods before and after SGLT2 inhibitor administration were 2.6 and 1.9 years, respectively. Changing rates of eGFR per year were significantly improved after treatment with SGLT2 inhibitors (−5.78 ± 7.67 to −0.43 ± 10.81 mL/min/1.73 m2/year, p = 0.006). The daily doses of loop diuretics were not altered after SGLT2 inhibitor administration. Neither decreased body weight nor increased hematocrit was associated with the change in eGFR slope before and after SGLT2 inhibitor administration. While, the decrease in inferior vena cava diameter and the increase in its respiratory collapsibility were significantly correlated with the improvement of eGFR decline slope after SGLT2 inhibitor administration. Conclusions: Our findings indicated that chronic treatment with SGLT2 inhibitors ameliorated annual decline in eGFR in Japanese patients with chronic heart failure, suggesting the possibility that the improvement of venous congestion was involved in its renoprotective effect.

Published
2022
Full Text
View/download PDF

2. Long-term administration of tolvaptan ameliorates annual decline in estimated glomerular filtration rate in outpatients with chronic heart failure

Author

Ryutaro Yoshimura, Yuya Sakamoto, Go Yokouchi, Noriaki Kasayuki, Yasuhiro Izumiya, Minoru Yoshiyama, Haruo Nakamura, Kohei Fujimoto, T Horio, Ryosuke Fujiwara, Yujiro Matsuoka, and Kazuhiro Nakao

Subjects
medicine.medical_specialty, Tolvaptan, Renal function, 030204 cardiovascular system & hematology, Egfr decline, Inferior vena cava, Annual change, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Outpatients, medicine, Humans, 030212 general & internal medicine, Retrospective Studies, Heart Failure, business.industry, Vascular surgery, Benzazepines, medicine.disease, Cardiac surgery, medicine.vein, Heart failure, Chronic Disease, Cardiology, Cardiology and Cardiovascular Medicine, business, Antidiuretic Hormone Receptor Antagonists, medicine.drug, Glomerular Filtration Rate
Abstract

Protective effects of tolvaptan against worsening renal function in acute heart failure have been shown. However, long-term effects of its agent on renal function remain to be elucidated. The present study investigated retrospectively whether long-term treatment with tolvaptan exerts renoprotective effects in patients with chronic heart failure, by comparing serial changes in estimated glomerular filtration rate (eGFR) for years before and after tolvaptan administration. From 63 outpatients with chronic heart failure taking diuretics including tolvaptan, 34 patients whose eGFR levels were continuously measured for more than 6 months both before and after administration of tolvaptan (average dose, 7.8 mg/day at the end of the follow-up period) were selected as eligible for the present analyses. All eGFR values were separately plotted before and after the initiation of treatment with tolvaptan (except hospitalization periods) along the time course axis and the slope of the linear regression curve was calculated as an annual change in eGFR. The mean follow-up periods before and after tolvaptan administration were 1197 and 784 days (3.3 and 2.1 years), respectively. Changing rates of eGFR per year were significantly ameliorated after treatment with tolvaptan (mean ± SD, − 8.02 ± 9.35 to − 1.62 ± 5.09 mL/min/1.73m2 /year, P = 0.001). In echocardiographic parameters, inferior vena cava (IVC) diameter significantly decreased after tolvaptan administration, and the decrease in IVC diameter was correlated with the improvement of eGFR decline slope after administration of tolvaptan (P = 0.0075). This longitudinal observational study indicated that long-term treatment with tolvaptan ameliorated annual decline in eGFR in outpatients with chronic heart failure. Our findings suggest that tolvaptan has a protective effect against chronically worsening renal function in heart failure patients.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results